Scientific intelligence record
Experience 2.0
Direct thrombin inhibitor peptide
Bivalirudin is a synthetic 20-residue peptide anticoagulant derived conceptually from the thrombin-binding properties of hirudin. Its N-terminal D-phenylalanine-containing sequence binds the catalytic site of thrombin while a C-terminal region engages thrombin’s fibrin-recognition exosite; thrombin can subsequently cleave the molecule, contributing to reversible inhibition. It acts directly on circulating and clot-bound thrombin without requiring antithrombin. The molecule is established in percutaneous coronary intervention, while use in extracorporeal membrane oxygenation, cardiopulmonary bypass, pediatric procedures, and other settings has a different and often off-label evidence and regulatory context.
Record status
Traceability partial
Last meaningful update: 9/20/2026
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Europe PMC · 2026 · PMID 41337754 · DOI 10.1097/mat.0000000000002598
human-observational
Europe PMC · 2026 · PMID 42562730 · DOI 10.1053/j.jvca.2026.07.012
preclinical-animal
Europe PMC · 2026 · PMID 41710639 · DOI 10.4103/sja.sja_422_25
preclinical-animal
Europe PMC · 2026 · PMID 42255777 · DOI 10.7759/cureus.108325
human-observational
Europe PMC · 2026 · PMID 41692040 · DOI 10.1016/j.jvs.2026.02.007
human-interventional
Europe PMC · 2026 · PMID 41754906 · DOI 10.3390/pharmaceutics18020163
preclinical-animal
Europe PMC · 2026 · PMID 42273795 · DOI 10.1097/mat.0000000000002758
human-observational
Europe PMC · 2026 · PMID 42509130 · DOI 10.1053/j.jvca.2026.07.009
preclinical-animal
Europe PMC · 2026 · PMID 41384770 · DOI 10.1097/aco.0000000000001603
preclinical-animal
Europe PMC · 2026 · PMID 40778562 · DOI 10.1024/0301-1526/a001220
human-observational
Europe PMC · 2026 · PMID 41853585 · DOI 10.1016/j.rpth.2026.103389
human-observational
Europe PMC · 2026 · PMID 42643974 · DOI 10.3389/fped.2026.1902882
human-observational
Europe PMC · 2026 · PMID 42079980 · DOI 10.1016/j.xjon.2026.101703
human-observational
Europe PMC · 2026 · PMID 41654428 · DOI 10.1016/j.transproceed.2026.01.020
human-observational
Europe PMC · 2026 · PMID 42604760 · DOI 10.1111/ijlh.70223
preclinical-animal
Europe PMC · 2026 · PMID 41823520 · DOI 10.1097/pcc.0000000000003938
human-observational
Europe PMC · 2026 · PMID 42663356 · DOI 10.1016/j.jacc.2026.06.035
human-interventional
Europe PMC · 2026 · PMID 42602128 · DOI 10.1177/30502225261479091
human-interventional
Europe PMC · 2026 · PMID 42495070 · DOI 10.3389/fcvm.2026.1864489
human-observational
Europe PMC · 2026 · PMID 42256237 · DOI 10.1016/j.jhlto.2026.100591
human-observational
Europe PMC · 2026 · PMID 42137722 · DOI 10.14740/jmc5306
human-observational
Europe PMC · 2026 · PMID 42663361 · DOI 10.1016/j.jacc.2026.07.012
contextual-unclassified
Europe PMC · 2026 · PMID 41991390 · DOI 10.1053/j.jvca.2026.03.031
contextual-unclassified
Europe PMC · 2026 · PMID 42319156 · DOI 10.1097/sla.0000000000007128
human-observational
Europe PMC · 2026 · PMID 42635488 · DOI 10.1097/pcc.0000000000004038
contextual-unclassified
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
ANGIOMAX (bivalirudin) is FDA-approved as an intravenous anticoagulant for patients undergoing percutaneous coronary intervention, including patients with heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome.
FDA Drugs@FDA NDA 020873 and ANGIOMAX Prescribing InformationBivalirudin evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
D-residue stereochemistry is retained in notation and collapsed to X only for the schematic.
Sources: NIH PubChem — Bivalirudin · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). Bivalirudin — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/bivalirudin
AMA / Vancouver
World Peptide Foundation. Bivalirudin — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/bivalirudin
Ranked research corpus
500
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
500
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Bivalirudin no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Contrasting evidence exists on the comparative efficacy and safety of bivalirudin and unfractionated heparin (UFH) in relation to the planned use of glycoprotein IIb/IIIa inhibitors (GPIs).
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
1998 · study · Temporal status not established
The American journal of cardiology
2003 · study · Temporal status not established
JAMA
2006 · study · Temporal status not established
The New England journal of medicine
2008 · study · Temporal status not established
The New England journal of medicine
2011 · study · Temporal status not established
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
2013 · study · Temporal status not established
The New England journal of medicine
2014 · study · Temporal status not established
Lancet (London, England)
2015 · study · Temporal status not established
The New England journal of medicine
2015 · study · Temporal status not established
PloS one
2018 · study · Temporal status not established
Journal of the American College of Cardiology
2019 · study · Temporal status not established
Journal of the American College of Cardiology
2019 · study · Temporal status not established
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
2020 · study · Temporal status not established
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
2022 · study · Temporal status not established
Lancet (London, England)
2022 · study · Temporal status not established
Thrombosis research
2023 · study · Temporal status not established
The journal of applied laboratory medicine
2023 · study · Temporal status not established
Circulation
2023 · study · Temporal status not established
Perfusion
2023 · study · Temporal status not established
ASAIO journal (American Society for Artificial Internal Organs : 1992)
2023 · study · Temporal status not established
Frontiers in medicine
2024 · study · Temporal status not established
Cardiovascular revascularization medicine : including molecular interventions
2024 · study · Temporal status not established
Paediatric anaesthesia
2025 · study · Temporal status not established
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
2025 · study · Temporal status not established
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
2025 · study · Temporal status not established
Journal of clinical anesthesia
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
4 represented evidence records
Years represented: 2015, 2018, 2019, 2023
Publishing organizations appearing in records: Circulation, Journal of the American College of Cardiology, The New England journal of medicine
3 represented evidence records
Years represented: 2015, 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology, The New England journal of medicine
3 represented evidence records
Years represented: 2006, 2008, 2020
Publishing organizations appearing in records: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, The New England journal of medicine
3 represented evidence records
Years represented: 2015, 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology, The New England journal of medicine
3 represented evidence records
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Bivalirudin evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/9/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/9/2026 · Temporal status not established
FDA Drugs@FDA NDA 020873 and ANGIOMAX Prescribing Information
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:19 AM
5 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The value of prolonged bivalirudin infusion after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with or without ST-segment elevation remains unclear.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic complications in patients with stable angina and non-ST-segment elevation acute coronary syndromes who are undergoing percutaneous coronary intervention (PCI).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin, with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of care in primary percutaneous coronary intervention (PPCI).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Previous randomised trials of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) have reported conflicting results, in part because of treatment with different pharmacological regimens.
To test feasibility of a randomized controlled trial (RCT) with an endpoint of time at goal anticoagulation in children on extracorporeal membrane oxygenation (ECMO) randomized to receive bivalirudin vs.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Pediatric physicians regularly face the problem of uncertain procedural anticoagulation in children, especially in neonates.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The dosing of anticoagulants during coronary angioplasty is commonly guided by measurements of activated clotting time (ACT), but the usefulness of these measurements remains uncertain.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Direct thrombin inhibitors (DTIs) are usually monitored with the activated partial thromboplastin time (aPTT) or activated clotting time (ACT).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non-ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
We sought to evaluate the efficacy and safety of bivalirudin versus heparin in patients with coronary artery disease undergoing transradial artery coronary intervention (TRI).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To evaluate the efficacy of post-primary percutaneous coronary intervention (PCI) bivalirudin infusion (at full PCI dose) to prevent stent thrombosis (ST) compared with heparin monotherapy.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing cardiac ischemic events, but with a lower bleeding risk.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin has been suggested as an alternative to heparin for anticoagulation in patients receiving extracorporeal membrane oxygenation (ECMO).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The effect and safety of bivalirudin compared with heparin in patients undergoing extracorporeal membrane oxygenation (ECMO) remains unclear.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Optimal anticoagulation therapy is essential for the prevention of thrombotic and hemorrhagic complications in pediatric patients supported with extracorporeal membrane oxygenation (ECMO).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin is an alternative accepted therapy to unfractionated heparin for patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Anticoagulation is important for extracorporeal membrane oxygenation (ECMO).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin is a direct thrombin inhibitor used off-label for systemic anticoagulation in extracorporeal membrane oxygenation (ECMO).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin is recommended as an alternative to heparin in cardiac surgery with cardiopulmonary bypass.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Bivalirudin infusions are traditionally monitored with activated partial thromboplastin time (aPTT) despite the poor correlation with bivalirudin dose-response curves.
Years represented: 2015, 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology, The New England journal of medicine
2 represented evidence records
Years represented: 2003, 2006
Publishing organizations appearing in records: JAMA, The New England journal of medicine
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology
2 represented evidence records
Years represented: 2003, 2006
Publishing organizations appearing in records: JAMA, The New England journal of medicine
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology
2 represented evidence records
Years represented: 2015, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology, The New England journal of medicine
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology
2 represented evidence records
Years represented: 2018, 2019
Publishing organizations appearing in records: Journal of the American College of Cardiology